RAF1 and cancer: The oral multikinase inhibitor sorafenib (Nexavar®) suppresses tumor growth by targeting Raf serine/threonine kinases (Raf-1, wild-type B-Raf, and oncogenic B-Raf V600E) and receptor tyrosine kinases (VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-β, Flt-3, and c-Kit) in a variety of human cancers [69].